Jinyu Bio-Technology Co

Jinyu Bio-Technology Co FCF/Debt

The Free Cash Flow to Debt Ratio of Jinyu Bio-Technology Co (600201.SS) as of Oct 27, 2026 is 1,229.30 %. In the previous year, Free Cash Flow to Debt Ratio was 5,180.13 % — a change of -76.27% (lower).

FCF/Debt

1,229.30 %

YoY

-76.27%

Last updated:

Free Cash Flow to Debt Ratio of Jinyu Bio-Technology Co is 2024 1,229.30 % . Free Cash Flow to Debt Ratio of Jinyu Bio-Technology Co was 2023 5,180.13 % . It decreases by -76.27% lower compared to the previous year.

The Jinyu Bio-Technology Co FCF/Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF/Debt
Date
FCF/Debt
Jan 1, 2017
18,972.37 CNY
Jan 1, 2018
-4,767.68 CNY
Jan 1, 2019
244.22 CNY
Jan 1, 2020
480.68 CNY
Jan 1, 2021
20,661.51 CNY
Jan 1, 2022
1,423.86 CNY
Jan 1, 2023
5,180.13 CNY
Jan 1, 2024
1,229.30 CNY
The Jinyu Bio-Technology Co FCF/Debt history
YEARFCF/DebtYoY
1,229.30 %-76.27%
5,180.13 %+263.81%
1,423.86 %-93.11%
20,661.51 %+4,198.39%
480.68 %+96.82%
244.22 %-105.12%
-4,767.68 %-125.13%
18,972.37 %-84.75%
124,374.70 %+168.01%
46,405.98 %-38.71%
75,711.17 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Jinyu Bio-Technology Co Stock analysis

What does Jinyu Bio-Technology Co do? Jinyu Bio-Technology Co., Ltd. generates revenue by researching, developing, producing, and selling veterinary biological products, with a primary focus on veterinary vaccines. The company operates from its headquarters in Hohhot, Neimenggu, where it employs 1,618 full-time staff members to support these core activities. In addition to its main veterinary operations, the firm diversifies its income streams by engaging in textile processing, providing energy products, and offering property leasing and management activities. These supplementary services allow the company to serve various market segments beyond the veterinary sector. The business model relies on the direct sale of its veterinary vaccines and biological products to customers in the animal health industry. By integrating manufacturing with research and development, Jinyu Bio-Technology Co., Ltd. maintains control over its product quality and supply chain while expanding into related industrial and service areas. Jinyu Bio-Technology Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Jinyu Bio-Technology Co stock

Free Cash Flow to Debt Ratio of Jinyu Bio-Technology Co is 1,229.30 % in 2024.

Free Cash Flow to Debt Ratio of Jinyu Bio-Technology Co changed from 5,180.13 % to 1,229.30 %, representing a -76.27% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Free Cash Flow to Debt Ratio Jinyu Bio-Technology Co since 2006 – with annual values, charts, and detailed analysis.

FCF/Debt measures the percentage of total debt that could be repaid from free cash flow. It is a stricter measure than OCF/Debt as it accounts for capital expenditures.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Free Cash Flow to Debt Ratio's Jinyu Bio-Technology Co with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Leverage — Jinyu Bio-Technology Co

Debt-to-EquityNet Debt / EBITDAInterest CoverageCurrent RatioQuick RatioCash RatioDebt / AssetsFinancial LeverageEquity RatioLT Debt/EquityNet Debt/EquityDebt/EBITDADSCRFinancial Debt RatioOCF/DebtFCF/DebtNet Debt/FCFDebt/Market Cap

All Key Metrics — Jinyu Bio-Technology Co